<font> NeoStem, Inc. </font> (AMEX:NBS)is a pioneer and leader in the pre-disease collection, processing and long-term storage of adult stem cells for the general population to use in future medical applications. The Company's business model includes generating revenue through ongoing fees associated with a minimally invasive, proprietary stem cell collection process, in addition to fees charged to the centers for marketing and long-term storage. NeoStem targets its marketing efforts toward health conscious consumers to encourage them to donate and store their stem cells as a form of bio-insurance for possible use in later years or to address an emerging medical need.
Pro-Active Research Group initiated coverage of NeoStem on 5/27/09 with a speculative buy rating and $5/share long-term price target. The PDF report is available to view or download for free at the
<font> BioMedReports.com stock research </font> reports section.
The following are investment highlights outlined in the NeoStem report: (1) it is the first company to offer adult stem cell collection and banking services to general adult population; (2) leadership team includes executives with extensive medical, scientific, and business experience; (3) recently concluded an $11 million financing for strategic growth initiatives in China and U.S.; (4) poised to become leader in medical tourism for wounds, orthopedics, and regenerative medicine; (5) recently announced licensing deals for adult stem cell based, regenerative medicine technologies; (6) rated speculative buy with long-term price target of $5/share (about $100M fully diluted market cap); and (7) positive news flow expected along with growth initiatives in China to fuel continued stock price gains.
Disclosure: No positions.
$2.6 (06/04/09)
